ERα ORF cDNA Lentivirus

Background

Estrogen receptor alpha (ERalpha), encoded by ESR1, is a ligand-activated nuclear receptor that mediates the biological effects of estrogens. Upon binding estradiol, ERalpha dimerizes, associates with coregulator proteins, and binds estrogen response elements in target gene promoters to regulate transcription; it can also act through nongenomic and tethered mechanisms. ERalpha governs development and function of the reproductive system, bone, cardiovascular tissue, and the central nervous system. It is a defining marker of hormone-receptor-positive breast cancer and the target of endocrine therapies such as tamoxifen and aromatase inhibitors, while ESR1 mutations are linked to endocrine therapy resistance. ERalpha is therefore a central focus of endocrine and cancer research.

Product Description & Applications

The ERalpha ORF cDNA Lentivirus enables stable overexpression of human estrogen receptor alpha (ESR1) in mammalian cells. Lentiviral particles are packaged with an expression vector encoding the ERalpha open reading frame driven by a CMV promoter, delivered through a third-generation, VSV-G pseudotyped system. Depending on configuration, the construct may include a C-terminal epitope tag, a fluorescent reporter (such as EGFP or mCherry), and an antibiotic selection marker (Blasticidin or Puromycin), with tag, reporter, and selection elements linked by self-cleaving peptide sequences to allow independent translation. Stable polyclonal cell lines are readily established by antibiotic selection or fluorescence-based sorting. Supplied as high-titer particles purified by PEG precipitation and sucrose gradient centrifugation, the product transduces primary and difficult-to-transfect cells for gain-of-function studies of estrogen receptor signaling and drug response.

About This Product

This ORF cDNA lentivirus enables stable overexpression of ESR1 (ERa) (NCBI Accession: NM_000125) in mammalian cells via a third-generation, VSV-G pseudotyped delivery system. The ORF cDNA is fused to a C-terminal epitope tag (V5, Myc, or HA) and expressed under a strong constitutive promoter (CMV). Reporter and selection marker components (EGFP, GFP, mCherry, RFP; Blasticidin, Puromycin) are co-expressed via self-cleaving P2A peptides, enabling independent protein production without fusion-tag artifacts.

Ultra-purification by PEG precipitation and sucrose gradient centrifugation yields high-titer particles suitable for primary cells, suspension cultures, and stem cells. Stable polyclonal cell lines are established within 10–14 days by antibiotic selection or FACS sorting. For in vivo applications, the serum-free formulation and VSV-G envelope support direct administration or further concentration for stereotactic injection.